Loading...
•
Sep 30, 2025
BioCryst Q3 2025 Earnings Report
BioCryst reported strong third quarter results driven by ORLADEYO revenue growth and a return to profitability.
Key Takeaways
BioCryst delivered strong Q3 2025 results with robust ORLADEYO sales pushing revenue to $159.4M and swinging to a net income of $12.9M from a loss last year. The company repaid its Pharmakon term debt and raised full-year guidance.
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
BioCryst raised full-year ORLADEYO revenue guidance and lowered expense forecasts, reflecting strong commercial execution and improved financial strength after debt repayment.
Positive Outlook
- ORLADEYO FY25 revenue guidance raised to $590M–$600M
- Non-GAAP operating expense guidance lowered to $430M–$440M
- Full-year profitability and positive cash flow reaffirmed
- Debt fully repaid following sale of European business
- ORLADEYO granules for children could receive approval by year-end
Challenges Ahead
- SG&A expenses rose due to transaction costs and reclassified items
- R&D spending increased due to pipeline advancements
- Net cash utilization still impacted by debt prepayment
- Interest income declined compared to previous year
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...